Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/10/15  and contains information from public web pages.

Mr. Marcus Drake

Wrong Marcus Drake?

Advisory Board Member

ICIQ Project
Company Description: What provides: Overview of the Modular Questionnaire structure Guidance regarding module selection User manuals for ICIQ modules Access to...   more

Employment History

  • Clinical Lecturer In Urology
    University of Newcastle
Web References
ICIQ | Advisory Board, 10 Jan 2015 [cached]
Mr Marcus Drake, Consultant Urological Surgeon
prostate newsbytes, 21 April 2002 [cached]
Lead researcher Dr Marcus Drake, clinical lecturer in urology at the University of Newcastle, said: "We are very excited about these findings.
Urologic Institute of New Orleans - Urology News, 7 April 2003 [cached]
Lead researcher Dr Marcus Drake, clinical lecturer in urology at the University of Newcastle, said: "We are very excited about these findings.
OxMed Editorial Board, 4 Feb 2002 [cached]
Mr Marcus J DrakeClinical lecturer in Urological Science,University of Newcastle upon Tyne. Formerly Specialist Registrar, Oxford Regional Higher Urology Training Scheme.Previous holder of the Buckson-Browne Research Fellowship, Royal College of Surgeons of England and the British Urological Foundation/Yamanouchi scholarship.
Tufts-NEMC - Health Information, 27 Mar 2003 [cached]
Researcher Dr. Marcus J. Drake, from the University of Newcastle in Newcastle-upon-Tyne, told Reuters Health the evidence suggests that thalidomide may extend life by blocking growth factors that stimulate the development of blood vessels to "feed" tumours.
"We are hoping that for those very high-risk patients, we may be able to supplement other treatments.By giving them thalidomide, we can reduce growth factors," he said.
Few drugs in the history of medicine have aroused as much controversy or fear as thalidomide.Originally introduced in Britain in 1958 as a sedative, it was widely prescribed to pregnant women in Europe to treat morning sickness.But within a couple of years doctors began to hear reports of terrible deformities in newborns.The drug was withdrawn in 1961.
In recent years, however, thalidomide has emerged as a potential therapy for a range of diseases including cancers.One of the reasons is that the drug has powerful anti-angiogenic properties, slowing the development of new blood vessels that feed tumours.
For the new research, reported in the March 24th issue of the British Journal of Cancer, Drake and colleagues recruited 20 men with progressive cancer who had failed to respond to hormone therapy.
Each was given a daily dose of thalidomide alongside continued hormone therapy.
Out of 16 men who stayed on the drug for at least two months, six experienced a drop in PSA levels of around 48 percent, with three of them seeing a decline of 50 percent or more.
However, patients did have side effects such as constipation, headache, nausea and weight gain.
The researchers conclude that thalidomide may be a useful treatment for some patients but needs close monitoring.
Other People with the name "Drake":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.